鼻内右美托咪定或咪达唑仑术前用药对扁桃体腺样体切除术患儿围术期呼吸不良事件的影响:一项随机临床试验
这项单中心、双盲随机临床试验纳入384例0-12岁择期扁桃体腺样体切除术患儿,随机分为鼻内咪达唑仑组(0.1 mg/kg)、鼻内右美托咪定组(2.0 μg/kg)和生理盐水对照组,主要终点为PRAEs发生率。调整年龄、性别、ASA分级、BMI、阻塞性睡眠呼吸暂停、上呼吸道感染和被动吸烟后,咪达唑仑组PRAEs发生率显著高于生理盐水组(56.5% vs 40.8%;aOR 1.99;95% CI 1.18-3.35),右美托咪定组显著低于生理盐水组(24.2% vs 40.8%;aOR 0.45;95% CI 0.26-0.78);咪达唑仑组PRAEs风险高于右美托咪定组(aOR 4.44;95% CI 2.54-7.76),未观察到其他严重临床不良事件。作者认为,在临床适当时,麻醉医师可考虑使用鼻内右美托咪定用于此类患儿的镇静。
要点
- 在0-12岁择期扁桃体腺样体切除术患儿中,鼻内右美托咪定(2.0 μg/kg)组PRAEs发生率为24.2%(30/124),低于生理盐水组的40.8%(51/125),aOR 0.45(95% CI 0.26-0.78)。
- 鼻内咪达唑仑(0.1 mg/kg)组PRAEs发生率为56.5%(70/124),高于生理盐水组的40.8%(51/125),aOR 1.99(95% CI 1.18-3.35)。
- 咪达唑仑组PRAEs风险高于右美托咪定组,aOR 4.44(95% CI 2.54-7.76)。
- 研究未观察到其他严重临床不良事件;作者认为临床适当时麻醉医师可考虑使用鼻内右美托咪定镇静。
适用人群与场景
- 0-12岁(中位[IQR]年龄7[5-10]岁)拟行择期扁桃体腺样体切除术的患儿,来自中国徐州医科大学附属儿童医院,招募时间为2020年10月至2021年6月。
- 共384例患儿纳入并随机化,其中373例数据集纳入意向性治疗分析(咪达唑仑组124例、右美托咪定组124例、生理盐水组125例);男孩227例(59.1%)。
处置流程与药物剂量
- 咪达唑仑组:鼻内给予咪达唑仑0.1 mg/kg作为术前用药。
- 右美托咪定组:鼻内给予右美托咪定2.0 μg/kg作为术前用药。
- 生理盐水组:鼻内给予0.9%生理盐水作为对照。
- 作者认为,在临床适当时,麻醉医师可考虑使用鼻内右美托咪定用于接受扁桃体腺样体切除术的患儿镇静。
研究设计与关键结果
- 研究类型:单中心、双盲、随机临床试验;纳入384例0-12岁择期扁桃体腺样体切除术患儿,373例纳入意向性治疗分析(咪达唑仑组124例、右美托咪定组124例、生理盐水组125例)。
- 主要终点:调整年龄、性别、美国麻醉医师协会(ASA)体格状态、体重指数、阻塞性睡眠呼吸暂停、上呼吸道感染和被动吸烟后,咪达唑仑组PRAEs发生率56.5%(70/124)高于生理盐水组40.8%(51/125),aOR 1.99(95% CI 1.18-3.35);右美托咪定组PRAEs发生率24.2%(30/124)低于生理盐水组40.8%(51/125),aOR 0.45(95% CI 0.26-0.78)。
- 咪达唑仑组PRAEs风险高于右美托咪定组,aOR 4.44(95% CI 2.54-7.76)。
- 未观察到其他严重临床不良事件。
证据类型、等级与局限
- 证据类型:单中心、双盲、随机临床试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在0-12岁择期扁桃体腺样体切除术患儿中,鼻内咪达唑仑0.1 mg/kg术前用药与PRAEs发生率增加相关(56.5% vs 40.8%;aOR 1.99;95% CI 1.18-3.35),鼻内右美托咪定2.0 μg/kg术前用药与PRAEs发生率降低相关(24.2% vs 40.8%;aOR 0.45;95% CI 0.26-0.78)。
- 作者认为,在临床适当时,麻醉医师可考虑使用鼻内右美托咪定用于接受扁桃体腺样体切除术的患儿镇静。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Perioperative respiratory adverse events (PRAEs) are the most common complication during pediatric anesthesia, and they may be affected by the administration of preoperative sedatives.
OBJECTIVE: To investigate the effect of intranasal dexmedetomidine or midazolam used for premedication on the occurrence of PRAEs.
DESIGN, SETTING, AND PARTICIPANTS: This single-center, double-blind, randomized clinical trial was conducted among children aged 0 to 12 years undergoing elective tonsillectomy and adenoidectomy from October 2020 to June 2021 at Children's Hospital of Xuzhou Medical University, Xuzhou, China. Data analysis was performed from June to October 2021.
INTERVENTIONS: Children were randomly assigned to 3 groups: the midazolam group received intranasal midazolam (0.1 mg/kg), and the dexmedetomidine group received intranasal dexmedetomidine (2.0 μg/kg) for premedication. The normal saline group received intranasal 0.9% saline for control.
MAIN OUTCOMES AND MEASURES: The primary outcome was the difference in the incidence of PRAEs among the 3 groups. The secondary outcomes were the frequency of the individual PRAEs, including the incidence of such events during the induction and recovery periods, postoperative emergence delirium, postoperative pain score, sedation success rate, and heart rate values.
RESULTS: A total of 384 children (median [IQR] age, 7 [5-10] years; 227 boys [59.1%]) were enrolled and randomized; 373 data sets were available for intention-to-treat analysis (124 children in the midazolam group, 124 children in the dexmedetomidine group, and 125 children in the normal saline group). After the data were adjusted for age, sex, American Society of Anesthesiologists physical status, body mass index, obstructive sleep apnea, upper respiratory tract infection, and passive smoking, children in the midazolam group were more likely to experience PRAEs than those in the normal saline group (70 of 124 children [56.5%] vs 51 of 125 children [40.8%]; adjusted odds ratio [aOR], 1.99; 95% CI, 1.18-3.35), whereas the dexmedetomidine group had a significantly lower PRAEs incidence than the normal saline group (30 of 124 children [24.2%] vs 51 of 125 children [40.8%]; aOR, 0.45; 95% CI, 0.26-0.78). Compared with the dexmedetomidine group, the midazolam group had a higher risk of PRAEs (aOR, 4.44; 95% CI, 2.54-7.76), but no other serious clinical adverse events were observed.
CONCLUSIONS AND RELEVANCE: In this randomized clinical trial, intranasal midazolam used for premedication was associated with increased incidence of PRAEs, whereas premedication with intranasal dexmedetomidine was associated with reduced incidence of PRAEs. Where clinically appropriate, anesthesiologists should consider using intranasal dexmedetomidine for sedation in children undergoing tonsillectomy and adenoidectomy.
TRIAL REGISTRATION: Chinese Clinical Trial Register Identifier: ChiCTR2000038359.
参考来源
- Shen F, Zhang Q, Xu Y, et al. Effect of Intranasal Dexmedetomidine or Midazolam for Premedication on the Occurrence of Respiratory Adverse Events in Children Undergoing Tonsillectomy and Adenoidectomy: A Randomized Clinical Trial. JAMA Netw Open. 2022. PMID: 35943745. doi:10.1001/jamanetworkopen.2022.25473
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。